Posts Tagged ‘semaglutide’

When people take a GLP-1 like semaglutide, osteoarthritis often improves. It makes sense. Excess body weight puts a strain on joints, especially the knee. And randomized controlled studies document the clinical benefits. New research confirms what clinical scientists have long suspected. Treating obesity can do more than just relieve the strain of excess weight on […]

It would be hard to find a sharper contrast than the one displayed yesterday in the report of fourth quarter 2025 business results for Eli Lilly and Novo Nordisk. Lilly is enjoying the best of times. Novo is suffering the worst. “Eli Lilly’s GLP-1 growth is only getting started,” says CNBC, “as Novo Nordisk braces […]

Usually, when new medicines have been on the market for a time, warnings tend to accumulate in the prescription labeling. So it is a bit unusual to see the FDA move to remove a warning. But recently, that’s exactly what happened with semaglutide and tirzepatide. FDA is making a course correction on warnings about suicidal […]

As we move through the first month of real-world utilization, Wegovy tablets are showing unexpectedly strong uptake for obesity – getting a head start on the anticipated arrival of Lilly’s orforglipron. Early utilization data suggest Wegovy in an oral form might be carving out meaningful space in obesity, defying initial skepticism. The Skepticism When enthusiasm […]

A big change is afoot and the hype is cranking up. With the launch of Wegovy tablets by Novo Nordisk yesterday, we are seeing some very big expectations expressed for a new era in obesity care. The stock market has boosted the value of Novo stock by 15 percent since FDA approved these tablets. Yesterday […]

It is no secret that alcohol use disorder is a risk after metabolic and bariatric surgery. The risk rises as time passes after surgery, with one study finding three percent of patients followed for a median of six years having one alcohol use disorder diagnosis in their medical records. Another study found that three years […]

News from Lilly about orforglipron this week points to what might be the next big development for GLP-1 medicines. The company announced topline results for a weight maintenance study of orforglipron and this first glimpse has us thinking that maintain might be the magic word in obesity care next year. The topline come from the […]

Truveta this week published data that reveals striking growth in the use of GLP-1s by women with PCOS (polycystic ovary syndrome). Prescriptions for semaglutide or tirzepatide have risen by more than 700% in women with PCOS, according to their analysis. So don’t think that this is slipping right by the bean counters at drug benefit […]

A new research letter in JAMA tells us that more new mothers are using GLP-1s for weight management. The rise of use in this context is dramatic – roughly 500% between 2022 and 2024. Note that these data come from Denmark. There, we estimate the per capita use of GLP-1s for obesity is somewhat less […]

Novo Nordisk made a bold gamble on oral semaglutide for delaying the progression of Alzheimer’s disease. Yesterday, as can happen with bold gambles, it did not pay off. A daily 14 mg oral dose of semaglutide was no better than placebo for preventing disease progression as measured by the Clinical Dementia Rating – Sum of […]